Aytu BioPharma IncAYTU
Price$2.14

Outlook & Key Dates

Estimates, guidance, catalysts, and upcoming events

Analyst Estimates Learn more →
Analyst Coverage
3analysts covering
As of 18 Aug 2026
FY EPS (est.)
-$1.14next fiscal year
As of 18 Aug 2026
Monitoring Framework
Key Performance Indicators
EXXUA Net Revenue Quarterly2.4MTarget: Growth driver following mid-January 2026 formal commercial launch
ADHD Portfolio Net Revenue Quarterly9.1MTarget: Maintain profitability despite generic competition for Adzenys
Cash and Cash Equivalents Quarterly26.7MTarget: Maintain sufficient liquidity to fund EXXUA commercialization
Watch Items
  • EXXUA Prescriber Adoption and Refill RatesTrigger: Transition of initial no-cost guarantee prescriptions to month 3 refillsAction: Monitor June 2026 quarter results and beyond for net revenue recognition improvements as guarantees are removed
  • Quarterly Net Revenue Breakeven TargetTrigger: $16.6 million for cash breakeven and $17.3 million for full breakevenAction: Evaluate cost management efficiency and gross margin stability in the mid-to-high 60% range
Sign in / Sign up to read more

Research as of 20 Jun 2026

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.